Nurix Therapeutics Inc’s recently made public that its Chief Legal Officer Ring Christine unloaded Company’s shares for reported $0.13 million on Dec 02 ’24. In the deal valued at $21.73 per share,5,760 shares were sold. As a result of this transaction, Ring Christine now holds 28,084 shares worth roughly $0.6 million.
Then, CHRISTINE RING bought 5,760 shares, generating $127,354 in total proceeds.
Before that, Ring Christine sold 3,290 shares. Nurix Therapeutics Inc shares valued at $82,250 were divested by the Chief Legal Officer at a price of $25.00 per share. As a result of the transaction, Ring Christine now holds 28,084 shares, worth roughly $0.6 million.
BMO Capital Markets initiated its Nurix Therapeutics Inc [NRIX] rating to an Outperform in a research note published on December 06, 2024; the price target was $35. A number of analysts have revised their coverage, including UBS’s analysts, who began to cover the stock in late October with a ‘”a Buy”‘ rating. Jefferies began covering NRIX with “Buy” recommendation on October 11, 2024.
Price Performance Review of NRIX
On Friday, Nurix Therapeutics Inc [NASDAQ:NRIX] saw its stock jump 6.53% to $21.37. Over the last five days, the stock has lost -3.35%. Nurix Therapeutics Inc shares have risen nearly 107.07% since the year began. Nevertheless, the stocks have risen 156.39% over the past one year. While a 52-week high of $29.56 was reached on 11/11/24, a 52-week low of $7.65 was recorded on 01/29/24. SMA at 50 days reached $23.79, while 200 days put it at $19.54.
Levels Of Support And Resistance For NRIX Stock
The 24-hour chart illustrates a support level at 20.48, which if violated will result in even more drops to 19.59. On the upside, there is a resistance level at 22.17. A further resistance level may holdings at 22.97. The Relative Strength Index (RSI) on the 14-day chart is 41.33, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.91, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 55.66%. Stochastics %K at 16.60% indicates the stock is a buying.
How much short interest is there in Nurix Therapeutics Inc?
A steep rise in short interest was recorded in Nurix Therapeutics Inc stocks on 2024-11-15, growing by 0.36 million shares to a total of 9.6 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 9.24 million shares. There was a rise of 3.78%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 31, 2024 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $36 price target.
